CG100649: Preliminary Phase I data

Preliminary data from a multiple-ascending dose, South Korean Phase I trial in 48 healthy volunteers showed that 2, 4 and 8 mg/day doses of GC100649 led to no drug-related gastrointestinal or cardiova...